{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:23:02Z","timestamp":1781803382415,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["305056\/2019-0"],"award-info":[{"award-number":["305056\/2019-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.biopha.2021.112054","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T22:58:36Z","timestamp":1630018716000},"page":"112054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["New potential antiproliferative monophosphoester 2-aminoethyl dihydrogen phosphate in K-562 and K-562 MDR+ leukemia cells"],"prefix":"10.1016","volume":"142","author":[{"given":"TO.","family":"Concei\u00e7\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LGS.","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MG.","family":"Laveli-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JC.","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MG.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DC.","family":"Rabelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RAN.","family":"Laiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DA.","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112054_bib1","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.msec.2016.11.073","article-title":"Liposome-based drug co-delivery systems in cancer cells","volume":"71","author":"Zununi Vahed","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.biopha.2021.112054_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.critrevonc.2015.08.020","article-title":"Chronic myeloid leukemia: relevance of cytogenetic and molecular assays","volume":"97","author":"Bennour","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.biopha.2021.112054_bib3","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/s41409-019-0513-5","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry","volume":"54","author":"L\u00fcbking","year":"2019","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"10.1016\/j.biopha.2021.112054_bib4","first-page":"56","article-title":"Multidrug resistance in tumour cells: characterisation of the multidrug resistant cell line K562-Lucena 1","volume":"73","author":"Rumjanek","year":"2001","journal-title":"Acad. Bras. Cienc."},{"issue":"9","key":"10.1016\/j.biopha.2021.112054_bib5","first-page":"645","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"J. Med."},{"key":"10.1016\/j.biopha.2021.112054_bib6","first-page":"609","article-title":"New England Journal CREST","volume":"360","author":"Fleischmann","year":"2009","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.biopha.2021.112054_bib7","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.112054_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fong","year":"2012","journal-title":"New Engl. J. Med."},{"issue":"24","key":"10.1016\/j.biopha.2021.112054_bib9","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2021.112054_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0006-8993(87)90471-9","article-title":"Phosphoethanolamine and ethanolamine are decreased in Alzheimer\u2019s disease and Huntington\u2019s disease","volume":"417","author":"Ellison","year":"1987","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.biopha.2021.112054_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.phymed.2009.07.009","article-title":"Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells","volume":"17","author":"Lage","year":"2010","journal-title":"Phytomedicine"},{"issue":"6","key":"10.1016\/j.biopha.2021.112054_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopha.2013.01.012","article-title":"Synthetic phosphoethanolamine induces cell cycle arrest and apoptosis in human breast cancer MCF-7 cells through the mitochondrial pathway","volume":"67","author":"Ferreira","year":"2013","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2021.112054_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pmn.2011.04.006","article-title":"Development and validation of a Brazilian version of the short-form McGill pain questionnaire (SF-MPQ)","volume":"14","author":"Ferreira","year":"2013","journal-title":"Pain. Manag. Nurs. Off. J. Am. Soc. Pain. Manag. Nurses"},{"issue":"7","key":"10.1016\/j.biopha.2021.112054_bib14","first-page":"408","article-title":"Meclizine chloridrate and methyl-\u03b2-cyclodextrin associated with monophosphoester synthetic phosphoethanolamine modulating proliferative potential in triple-negative breast cancer cells","volume":"7","author":"Laveli-Silva","year":"2019","journal-title":"J. Pharm. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2021.112054_bib15","first-page":"434","article-title":"Phosphomonoester phosphoethanolamine induces apoptosis in human chronic myeloid leukemia cells","volume":"7","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"J. Pharm. Pharm."},{"key":"10.1016\/j.biopha.2021.112054_bib16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2147\/IJN.S90850","article-title":"Potential antitumor activity of novel DODAC\/PHO-S liposomes","volume":"11","author":"Luna","year":"2016","journal-title":"Int J. Nanomed."},{"issue":"999","key":"10.1016\/j.biopha.2021.112054_bib17","first-page":"289","article-title":"Potential of liposomes for enhancement of oral drug absorption","volume":"14","author":"Daeihamed","year":"2017","journal-title":"Curr. Drug Deliv."},{"issue":"2","key":"10.1016\/j.biopha.2021.112054_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2012.01.005","article-title":"Rational design of new product candidates: the next generation of highly deformable bilayer vesicles for noninvasive, targeted therapy","volume":"160","author":"Cevc","year":"2012","journal-title":"J. Control Release"},{"issue":"24","key":"10.1016\/j.biopha.2021.112054_bib19","doi-asserted-by":"crossref","first-page":"16847","DOI":"10.18632\/oncotarget.24708","article-title":"Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells","volume":"9","author":"Catanzaro","year":"2018","journal-title":"Oncotarget"},{"issue":"January","key":"10.1016\/j.biopha.2021.112054_bib20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2019.01.045","article-title":"Aptamer-functionalized liposomes for targeted cancer therapy","volume":"448","author":"Moosavian","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2021.112054_bib21","unstructured":"T. Oliveira, Caracteriza\u00e7\u00e3o estrutural de agregados formados pelo antif\u00fangico anfotericina B e lip\u00eddios cati\u00f4nicos: uma poss\u00edvel formula\u00e7\u00e3o farmacol\u00f3gica. 2011:147. http:\/\/www.teses.usp.br\/teses\/disponiveis\/43\/43134\/tde-03032009-140235\/."},{"issue":"7","key":"10.1016\/j.biopha.2021.112054_bib22","first-page":"2039","article-title":"Chronic myeloid leukemia: standard treatment options","volume":"98","author":"Goldman","year":"2001","journal-title":"Am. J. Heal Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2021.112054_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.biopha.2021.112054_bib24","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2021.112054_bib25","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.biopha.2021.112054_bib26","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon Alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"New Engl. J. Med."},{"issue":"10","key":"10.1016\/j.biopha.2021.112054_bib27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2021.112054_bib28","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European leukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.biopha.2021.112054_bib29","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/jps.23146","article-title":"Molecular nanomedicine towards cancer","volume":"101","author":"Ho","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2021.112054_bib30","first-page":"219","article-title":"Nanoarchitectonics in biomedicine","author":"Jamp\u0131lek","year":"2019","journal-title":"Recent Adv. Lipid Nanocarriers Appl. Fight Cancer"},{"key":"10.1016\/j.biopha.2021.112054_bib31","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2147\/IJN.S90850","article-title":"Potential antitumor activity of novel DODAC\/PHO-S liposomes","volume":"11","author":"Luna","year":"2016","journal-title":"Int J. Nanomed."},{"issue":"1","key":"10.1016\/j.biopha.2021.112054_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-016-0433-9","article-title":"Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword","volume":"35","author":"Visconti","year":"2016","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"February","key":"10.1016\/j.biopha.2021.112054_bib33","first-page":"1","article-title":"Defective cell cycle checkpoints as targets for anti-cancer therapies","volume":"3","author":"Gabrielli","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112054_bib34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.toxlet.2012.10.008","article-title":"Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway","volume":"215","author":"Elumalai","year":"2012","journal-title":"Toxicol. Lett."},{"issue":"7","key":"10.1016\/j.biopha.2021.112054_bib35","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/cdd.2009.29","article-title":"Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway","volume":"16","author":"Inoue","year":"2009","journal-title":"Cell Death Differ."},{"issue":"21","key":"10.1016\/j.biopha.2021.112054_bib36","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1111\/j.1742-4658.2009.07329.x","article-title":"Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics","volume":"276","author":"Gillings","year":"2009","journal-title":"FEBS J."},{"issue":"9","key":"10.1016\/j.biopha.2021.112054_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrm2952","article-title":"Mitochondria and cell death: outer membrane permeabilization and beyond","volume":"11","author":"Tait","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2021.112054_bib38","first-page":"3","article-title":"Modified annexin V\/propidium iodide apoptosis assay for accurate assessment of cell death","volume":"50","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"issue":"3","key":"10.1016\/j.biopha.2021.112054_bib39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.bbrc.2011.06.186","article-title":"Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive\/propidium iodide-negative cells","volume":"411","author":"Sawai","year":"2011","journal-title":"Biochem. Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2021.112054_bib40","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1038\/s41418-020-0517-0","article-title":"MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1: NOXA complex","volume":"27","author":"Djajawi","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2021.112054_bib41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1083\/jcb.200708096","article-title":"A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation","volume":"180.2","author":"Lee","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2021.112054_bib42","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/sj.leu.2405039","article-title":"The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia","volume":"22.2","author":"Ploner","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2021.112054_bib43","first-page":"1","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9.1","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2021.112054_bib44","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/acs.jmedchem.9b00455","article-title":"From inhibition to degradation: targeting the antiapoptotic protein myeloid cell leukemia 1 (MCL1)","volume":"62.11","author":"Papatzimas","year":"2019","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2021.112054_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0962-8924(02)00043-0","article-title":"New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?","volume":"13","author":"Coqueret","year":"2003","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112054_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2018.05.018","article-title":"PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation","volume":"430","author":"Li","year":"2018","journal-title":"Cancer Lett."},{"issue":"November 2015","key":"10.1016\/j.biopha.2021.112054_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/emm.2015.115","article-title":"Estrogen-related receptor \u03b3 is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27","volume":"48","author":"Kim","year":"2016","journal-title":"Exp. Mol. Med."},{"issue":"10","key":"10.1016\/j.biopha.2021.112054_bib48","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1158\/1535-7163.MCT-07-0104","article-title":"P21 and P27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells","volume":"6","author":"Roy","year":"2007","journal-title":"Mol. Cancer Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221008374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221008374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:45:01Z","timestamp":1760100301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221008374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":48,"alternative-id":["S0753332221008374"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112054","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New potential antiproliferative monophosphoester 2-aminoethyl dihydrogen phosphate in K-562 and K-562 MDR+ leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112054"}}